RNACCartesian TherapeuticsRunning, no new patients
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Myasthaenia Gravis
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.3
A key executive is leaving
Since May 26, 2026 · was worth 15, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 128 (final count)
- Started
- May 6, 2025
- Main results expected
- Dec 30, 2026
- Fully finished
- Sep 30, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Myasthenia Gravis Activities of Daily Living (MG-ADL)
Measured over: assessment at 4 months of study
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 2.3, since 2026-05-26, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT06799247 · record last updated 2026-09-01 · checked 2026-11-09 15:47 UTC